A 350% premium for a stock with no product on the market, no revenues and really bad reviews. For example, just look at this very critical argument that encouraged the shorts.. http://www.fool.com/investing/general/2014/05/30/why-wall-street-hates-idenix-pharmaceuticals-inc.aspx My opinion -- this simply reflects the desperation of BP for pipeline. You know Denner is taking note as are the shareholders. Agree with BR, we should see a bounce today.